静脉性溃疡患者行激光消融联合髂静脉支架治疗非血栓性病变的结局
本研究回顾性分析157例活动性静脉性溃疡合并非血栓性髂静脉病变患者,比较单纯静脉腔内激光消融(EVLA)与EVLA联合髂静脉支架(EVLAS)的疗效。多变量分析表明肥胖和需站立职业是难治性溃疡预测因素,而髂静脉支架置入是溃疡愈合的保护因素。
要点
- 髂静脉支架置入是溃疡愈合的保护因素,肥胖和站立职业为难治性溃疡预测因素。
核心结论
- 在包含大隐静脉和穿通静脉消融的治疗方案中,联合髂静脉支架治疗非血栓性髂静脉病变与静脉性溃疡愈合成功率提高相关。
研究设计与样本
- 回顾性分析2017年1月至2019年12月收治的静脉性溃疡且诊断为非血栓性髂静脉病变的患者。
- 共纳入157例患者,其中EVLAS组93例,EVLA组64例。
- CT静脉造影显示髂静脉直径狭窄>50%者行经股静脉造影进一步确认。
主要发现
- 多变量分析显示肥胖和需站立职业是难治性溃疡的预测因素,髂静脉支架置入是溃疡愈合的保护因素。
临床怎么用
- 对于活动性静脉性溃疡合并非血栓性髂静脉病变的患者,在行大隐静脉和穿通静脉消融的同时,可考虑联合髂静脉支架置入以改善溃疡愈合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the clinical outcomes of superficial and perforator ablation and the effects on wound healing by adding iliac vein stenting of nonthrombotic iliac vein lesions (NIVLs) in patients presenting with active venous ulcers. METHODS: A retrospective analysis was performed of patients who had presented with venous ulcers and had a diagnosis of NIVLs from January 2017 to December 2019. Patients with a >50% diameter reduction in the iliac vein as determined by computed tomography venography had undergone transfemoral venography for further confirmation. Patients were divided into the endovenous laser ablation (EVLA) group and EVLA with stenting (EVLAS) group. The EVLA group had undergone endovascular laser treatment of superficial venous reflux, and the EVLAS group had undergone EVLA and stenting for NIVLs. The clinical outcomes were compared between the two groups. The primary end point was cumulative ulcer healing at 12 months. The secondary end points included complications, venous clinical severity score improvements, and pain scores during the follow-up period. Univariable and multivariable regression models were used to determine the refractory ulcer predictors. RESULTS: A total of 157 patients were included, 93 in the EVLAS group and 64 in the EVLA group. Of the 93 patients in the EVLAS group and patients in the EVLA group, 30 (32.26%) and 17 (26.56%) had presented with iliac venous occlusion, respectively (P = .48). The mean percentage of stenosis was 78.0% ± 13.6% in EVLAS group and 77.0% ± 14.0% in the EVLA group (P = .36). No significant differences in the general preoperative data were observed between the two groups. Cumulative ulcer healing at 1 year was 86.8% and 65.6% in the EVLAS and EVLA groups, respectively (P = .001). After a mean follow-up of 22 months (median, 24 months), the EVLAS group had a significantly improved venous clinical severity score compared with the EVLA group (EVLAS group, 8.3; EVLA group, 11.7; P = .01). Multivariable analysis of the entire cohort showed that obesity and employment that requires standing were predictive of refractory ulcers and that iliac venous stent placement was a protective factor for ulcer healing. CONCLUSIONS: The results of the present study have suggested an association between improvement in the overall success of venous leg ulcer healing when including treatment of NIVLs with stents into a treatment plan that already includes saphenous and perforator vein ablation.
引用
- Yang X, Wu X, Peng Z, et al. Outcomes of endovenous laser ablation with additional iliac vein stenting of nonthrombotic lesions in patients presenting with active venous ulcers. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33957281. doi:10.1016/j.jvsv.2021.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。